Suppression with Gonadotropin-Releasing Hormone Analogues Prior to Stimulation with Gonadotropins: Comparison of Three Protocols
- 1 January 1989
- journal article
- research article
- Published by S. Karger AG in Gynecologic and Obstetric Investigation
- Vol. 28 (1), 31-34
- https://doi.org/10.1159/000293495
Abstract
This study compared three groups of patients treated with three different protocols of suppression of the pituitary-ovarian axis prior to and during gonadotropin stimulation for in vitro fertilization with a nonsuppressed control group. Patients treated with daily injections of DTRp6 (Decapeptyl 0.5 mg) or with a single injection of Decapeptyl depot (3.2 mg CR) had a longer folicular phase than patients treated with Buserelin (1.2–1.5 mg daily) and the patients in the control group. The number of human menopausal gonadotropin ampules required to reach adequate stimulation was also significantly higher in the former two groups of patients. The number of oocytes recovered (6–7 per patient), fertilized (45–58%) and cleaved (92–100%) did not differ among the groups. Peak estradiol levels and the pregnancy rate were highest in the group treated with Buserelin. The overall picture would indicate that suppression with Buserelin was the least profound.Keywords
This publication has 5 references indexed in Scilit:
- Endocrine changes following pituitary desensitization with LHRH agonist and administration of purified FSH to induce follicular maturationBJOG: An International Journal of Obstetrics and Gynaecology, 1987
- Ovarian stimulation by a combination of a gonadotropin-releasing hormone agonist and gonadotropins for in vitro fertilizationFertility and Sterility, 1987
- Induction of multiple follicular growth in normally menstruating women with endogenous gonadotropin suppressionFertility and Sterility, 1986
- Specific binding of luteinizing hormone releasing hormone to human luteal tissueBiochemical and Biophysical Research Communications, 1983
- Induction of luteolysis by luteinizing hormone-releasing factor (LRF) agonist: sensitivity, reproducibility, and reversibilityFertility and Sterility, 1982